Inhibiting NOX enzymes to treat multiple diseases with high medical need
Posted 13th May 2019 by Joshua Sewell
NOX enzymes are a family of enzymes which amplify multiple signalling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.
Stem cell based anti-NASH drug testing: a pragmatic approach for a complex disease
Posted 29th April 2019 by Joshua Sewell
Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.
The Genetics of progressive NAFLD
Posted 24th April 2019 by Joshua Sewell
Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.
A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD
Posted 27th March 2019 by Joshua Sewell
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.
The Burden Of NASH
Posted 21st December 2018 by Jane Williams
The burden of non-alcoholic fatty liver disease (NAFLD) continues to increase at an alarming rate. The prevalence of disease equals the prevalence of metabolic syndrome (nearly 30% of the adult population), and NASH-cirrhosis represents the second cause for entering the waiting list for liver transplantation, with/without associated primary liver cancer.
Lipids versus hepatic inflammation: a lysosomal interplay
Posted 7th December 2018 by Jane Williams
The consumption of a healthy diet in combination with regular physical exercise is essential for an optimal and healthy condition, keeping the body in good shape. Although dietary guidelines may help in defining what is a healthy diet, the term healthy not only depends on individual needs and/or opinions.
Is Not Dying Yet on your bucket list?
Posted 30th November 2018 by Jane Williams
The Fatty Liver Foundation exists because I was not willing to be a well behaved member of the parade of misery that liver disease is becoming for our society. My bucket list includes not dying of liver disease.
The need for non-invasive diagnosis and monitoring of NASH
Posted 29th October 2018 by Jane Williams
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease and is increasing in prevalence as an etiology for end-stage liver disease and also hepatocellular carcinoma. NASH is often a silent disease and many patients have undiagnosed NASH for several years without experiencing any symptoms.
